INTRODUCTION {#s1}
============

Cancer is one of the major causes threatening human health and life \[[@R1]\]. Despite significant advances in diagnostic and treatment modalities, the average five-year survival rate for cancer patients is still extremely poor \[[@R2]\]. Stepwise accumulation of somatic genetic alterations is the basis for cancer which involved in base insertions, deletions, substitutions, translocation events, and copy number alteration \[[@R3]--[@R5]\]. The fact that targeted therapy has been successful in part of cancers calls for a better comprehension of the pathological mechanisms responsible for these oncogenic alterations leading to cancer.

Signal transducer and activator of transcription proteins 3 (STAT3), a member of STAT family, is well demonstrated to exerts an important effect on tumorigenesis and tumor-related inflammation \[[@R6]\]. Aberrant expression and persistent activation of STAT3 is implicated in cell proliferation, differentiation, apoptosis and immune escape, inducing and maintaining a pro-carcinogenic inflammatory microenvironment \[[@R7]\]. Continuously activated STAT3 has been found in many human tumors, such as lung cancer \[[@R8]\], gastric carcinoma \[[@R9]\], cervical carcinoma \[[@R10]\], and meningiomas \[[@R11]\]. Moreover, mounting evidence have demonstrated STAT3-targeted therapy could effectively inhibit tumor development in various human cancers \[[@R12]\]. However, the prognostic value of STAT3 overexpression in human tumors is still controversial. Therefore, in the current study, we carried out a systematic analysis combining thousands of gene expression or copy number variation analysis published online, to evaluate the expression pattern, potential functions and distinct prognostic value in cancer of STAT3.

RESULTS {#s2}
=======

To explore the role of STAT3 in cancers, we compared the transcription levels of STAT3 in cancers with that in normal tissues, using Oncomine database and found that the mRNA expressions of STAT3 were significantly over-expressed in certain types of tumors and lower in others as compared to that of the normal sample. As show in Figure [1](#F1){ref-type="fig"}, STAT3 may work either oncogenic or anti-oncogenic function based on the cancer types. Therefore, detailed analyses of STAT3 were described below.

![The transcription levels of STAT3 in different types of cancers\
This graphic was generated from Oncomine, indicating the numbers of datasets with statistically significant (*p* \< 0.01) mRNA over-expression (Red) or down-expression (Blue) of STAT3 (different types of cancer vs. corresponding normal tissue). The threshold was designed with following parameters: *p*-value of 1E-4, fold change of 2, and gene ranking of 10%.](oncotarget-09-3198-g001){#F1}

The transcript expression of STAT3 in different cancer types {#s2_1}
------------------------------------------------------------

We conducted cDNA microarray analysis by using the Oncomine database to explore gene expression of STAT3 in cancer types. The Oncomine database was queried for STAT3 expression in cancer and normal tissues. Our analysis revealed that STAT3 was over-expressed in brain and cns, gastric, head and neck, melanoma, myeloma cancers, but was under-expressed in breast, leukemia, liver, lymphoma, and sarcoma cancers as compared to that in normal tissue (Table [1](#T1){ref-type="table"}, Figure [2A--2C](#F2){ref-type="fig"}. [Supplementary Figures 1--3](#SD1){ref-type="supplementary-material"}) \[[@R13]--[@R28]\]. These observations are in agreement with the previously published reports on STAT3 expression \[[@R29]\]. For instance, our study indicated that STAT3 is highly expressed in glioblastoma (Figure [2B](#F2){ref-type="fig"}) \[[@R29]\], elevated in hepatocellular cancer ([Supplementary Figure 2B](#SD1){ref-type="supplementary-material"}) \[[@R30]\].

###### STAT3 expression in cancers

  Cancer              Cancer subtype                                       *p*-value   Fold change   Rank (%)   Sample   Reference
  ------------------- ---------------------------------------------------- ----------- ------------- ---------- -------- ------------
  **Brain**           Glioblastoma                                         2.81E-7     2.076         4          31       \[[@R13]\]
                      Glioblastoma                                         2.30E-10    2.270         7          104      \[[@R14]\]
  **Breast**          Ductal Breast Carcinoma                              1.00E-8     --2.176       2          47       \[[@R15]\]
                      Invasive Breast Carcinoma Stroma                     1.21E-15    --11.013      10         59       \[[@R16]\]
  **Gastric**         Gastric Mixed Adenocarcinoma                         6.45E-6     2.190         3          35       \[[@R17]\]
                      Gastric Intestinal Type Adenocarcinoma               2.26E-10    2.252         3          57       \[[@R17]\]
  **Head and Neck**   Salivary Gland Adenoid Cystic Carcinoma              7.94E-8     2.560         2          22       \[[@R18]\]
                      Tongue Carcinoma                                     1.81E-7     2.284         1          37       \[[@R19]\]
  **Leukemia**        B-Cell Acute Lymphoblastic Leukemia                  3.69E-41    --2.179       3          221      \[[@R20]\]
                      B-Cell Acute Lymphoblastic Leukemia                  1.76E-10    --2.669       5          93       \[[@R21]\]
                      T-Cell Acute Lymphoblastic Leukemia                  1.86E-6     --3.149       7          17       \[[@R21]\]
  **Liver**           Hepatocellular Carcinoma                             4.66E-9     --2.290       3          57       \[[@R22]\]
  **Lymphoma**        Burkitt's Lymphoma                                   9.06E-5     --2.746       8          42       \[[@R23]\]
  **Melanoma**        Cutaneous Melanoma                                   8.09E-5     8.442         10         52       \[[@R59]\]
  **Myeloma**         Monoclonal Gammopathy of Undetermined Significance   1.14E-5     2.213         7          66       \[[@R25]\]
  **Other**           Teratoma, NOS                                        1.34E-10    2.490         1          20       \[[@R26]\]
                      Pleural Malignant Mesothelioma                       6.05E-5     3.884         4          49       \[[@R27]\]
  **Sarcoma**         Myxoid/Round Cell Liposarcoma                        2.12E-5     --2.229       9          29       \[[@R28]\]

![STAT3 analysis in different cancer types (Oncomine database)\
The box plot comparing specific STAT3 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The fold change of STAT3 in various types of cancers was identified from our analyses in Table [1](#T1){ref-type="table"} and expressed as the forest plot (**A**). The analysis was shown in glioblastoma carcinoma relative to normal breast (**B**), in breast carcinoma relative to normal pancreatic (**C**).](oncotarget-09-3198-g002){#F2}

Genetic alterations of STAT3 and overall survival (OS) {#s2_2}
------------------------------------------------------

Using the comprehensive Kaplan-Meier survival analysis platform, we discovered that decreased mRNA expression of STAT3 is an unfavorable prognostic factor of overall survival for patients with breast adenocarcinoma (Figure [3](#F3){ref-type="fig"}). Contrastingly, lung, ovarian, and gastric cancers showed the relationship between overexpression of STAT3 and overall low survival rates (Figure [3](#F3){ref-type="fig"}).

![STAT3 genes in Breast, Ovarian, Gastric and Lung cancer (Kaplan--Meier Plotter)\
The survival curve comparing the patient with high (red) and low (black) expression in breast, ovarian, gastric and lung cancer was plotted from KaplanMeier plotter database.](oncotarget-09-3198-g003){#F3}

The prognostic value of STAT3 expression was reported by PrognoScan database (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The poor prognosis in ovarian cancer patients with higher STAT3 expression (Figure [5](#F5){ref-type="fig"}) was in line with the data from Kaplan--Meier plotter analysis (Figure [3](#F3){ref-type="fig"}). Using the comprehensive survival analysis platforms Kaplan-Meier plotter, Oncomine, and PrognoScan, we have demonstrated the oncogenic role of STAT3 in ovarian, lung, blood, and brain cancer, however, which is not clear in breast cancer.

![STAT3 genes in different cancer types (PrognoScan database)\
The statistically significant hazard ratio in various types of cancers was identified from our analyses in Table [2](#T2){ref-type="table"} and expressed as the forest plot. The analysis of survival curve was identified as the threshold of cox *p*-value \< 0.05.](oncotarget-09-3198-g004){#F4}

###### The association of STAT3 expression and the survival in cancer patients

  Cancer type      Dataset          Endpoint                           Probe id       *N*   Cox *p*-value   Hr
  ---------------- ---------------- ---------------------------------- -------------- ----- --------------- ------
  **Blood**        GSE12417-GPL97   Overall Survival                   243213_at      163   0.000744        1.69
  **Brain**        GSE4271-GPL97    Overall Survival                   243213_at      77    0.047646        1.91
  **Breast**       GSE3143          Overall Survival                   39708_at       158   0.031082        0.47
                   GSE7849          Disease Free Survival              39708_at       76    0.017328        4.53
                   GSE7849          Disease Free Survival              289_at         76    0.014144        4.92
                   GSE12276         Relapse Free Survival              208991_at      204   0.067027        0.75
                   GSE6532-GPL570   Relapse Free Survival              208991_at      87    0.015187        0.54
                   GSE6532-GPL570   Distant Metastasis Free Survival   208992_s\_at   87    0.012369        0.49
                   GSE6532-GPL570   Distant Metastasis Free Survival   208991_at      87    0.015187        0.54
                   GSE6532-GPL570   Relapse Free Survival              225289_at      87    0.046274        0.52
                   GSE6532-GPL570   Distant Metastasis Free Survival   225289_at      87    0.046274        0.52
                   GSE6532-GPL570   Relapse Free Survival              208992_s\_at   87    0.012369        0.49
                   GSE9195          Relapse Free Survival              208991_at      77    0.021717        3.80
                   GSE9195          Relapse Free Survival              243213_at      77    0.018195        8.75
                   GSE9195          Distant Metastasis Free Survival   243213_at      77    0.035491        9.33
                   GSE12093         Distant Metastasis Free Survival   208992_s\_at   136   0.016456        0.59
                   GSE12093         Distant Metastasis Free Survival   208991_at      136   0.005146        0.27
                   GSE11121         Distant Metastasis Free Survival   208992_s\_at   200   0.020347        0.44
                   GSE9893          Overall Survival                   21668          155   0.017780        0.69
                   GSE2034          Distant Metastasis Free Survival   208992_s\_at   286   0.015785        0.78
                   GSE2034          Distant Metastasis Free Survival   208991_at      286   0.003215        0.53
                   GSE2990          Relapse Free Survival              208991_at      62    0.037864        0.55
                   GSE2990          Relapse Free Survival              208992_s\_at   62    0.010824        0.33
  **Colorectal**   GSE17537         Disease Free Survival              225289_at      55    0.027763        0.21
  **Eye**          GSE22138         Distant Metastasis Free Survival   208992_s\_at   63    0.005425        2.00
                   GSE22138         Distant Metastasis Free Survival   208991_at      63    0.035231        1.66
  **Lung**         GSE31210         Relapse Free Survival              208992_s\_at   204   0.001112        4.53
                   GSE31210         Relapse Free Survival              225289_at      204   0.017076        4.72
                   GSE31210         Relapse Free Survival              243213_at      204   0.034308        0.54
                   GSE31210         Overall Survival                   208992_s\_at   204   0.047705        3.43
                   GSE8894          Relapse Free Survival              243213_at      138   0.002854        0.02
  **Ovarian**      GSE9891          Overall Survival                   208991_at      278   0.049049        0.74
  **Skin**         GSE19234         Overall Survival                   208991_at      38    0.008049        0.20

![STAT3 genes in blood, brain, lung and ovarian cancer types (PrognoScan database)\
The survival curve comparing the patient with high (red) and low (black) expression was plotted from PrognoScan database. The survival curve comparing the patient with high (red) and low (black) expression in blood cancer, brain cancer, lung cancer and ovarian cancer was plotted from PrognoScan database as the threshold of cox *p*-value \< 0.05.](oncotarget-09-3198-g005){#F5}

Protein components of nodes across the STAT3 {#s2_3}
--------------------------------------------

STAT homologs in mammals are comprised of six conserved structural domains, as follows: N-domain (ND), coiled-coil, DNA binding, linker, Src homology 2 (SH2), and transcriptional activation domain \[[@R31], [@R32]\]. Under normal physiological conditions, the activation of STATs is strictly regulated, which could regulate cell proliferation, survival and other critical cellular functions by modulating the expression of specific target genes. In cancer, by contrast, STAT protein, especially STAT3, become activated constitutively, thereby driving the malignant phenotype of cancer cells. We selected the functional protein partners of STAT3 based on previous publications and curated databases \[[@R6], [@R33]--[@R37]\]. Hence, the following nine predicted proteins, including cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), Interleukin-6 (IL6), Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), mitogen-activated protein kinase 1 (MAPK1), myelocytomatosis oncogene (MYC), suppressor of cytokine signaling3 (SOCS3), SRC were chose for further analysis of STAT3 (Figure [6](#F6){ref-type="fig"}).

![Identifcation of known and predicted structural proteins essential for STAT3 function\
Interacting nodes are displayed in colored circles using String, v10.0. Predicted functional partners of STAT3 are shown based upon peer reviewed published data and curated database entries. \[STRING v.10 (<http://string-db.org>)\].](oncotarget-09-3198-g006){#F6}

Unbiased cross cancer subtypes relationships by cBioPortal data {#s2_4}
---------------------------------------------------------------

When compared with the high frequency of STAT3 genetic deletions, there were few, frequent STAT3 gene mutations in 87 studies examined using cBioPortal Web. As show in Figure [7](#F7){ref-type="fig"}, a total of 300 mutation sites were detected and located between amino acids 0 and 770. STAT3 mutation mainly occurred in uterine cancer and existed in a hotspot in SH2 domain. In addition, we used cBioPortal tool to analyze the 10 gene of mutations and CNAs with 87 different cancer studies. The results analyzed 20 different cancer studies representing 8513 samples that contained \>40% alteration frequency and at least 100 samples in the dataset (Figure [8](#F8){ref-type="fig"}, Table [3](#T3){ref-type="table"}). From the lowest to highest dominance hierarchy, the ratio of alteration ranged over 40.1--67.9%. The particular interest constituted the predominant pattern of amplification occurring in neuroendocrine prostate cancer (NEPC).

![Mutation diagram of STAT3 in different cancer types across protein domains\
A total of 300 mutation sites were detected and located between amino acids 0 and 770. STAT3 mutation mainly occurred in uterine cancer and existed in a hotspot in SH2 domain.](oncotarget-09-3198-g007){#F7}

![Copy number alteration of STAT3 genes and cancer subtypes\
The alteration frequency of a ten-gene signature (CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC, STAT3) was determined using the cBioPortal (<http://www.cbioportal.org>). Only cancer types containing \>100 samples and an alteration frequency of \>40% are shown. The alteration frequency included deletions (blue), amplifcation (red), multiple alterations (grey) or mutation (green). The total number of samples for each cancer type are indicated by the numbers at the top of each column.](oncotarget-09-3198-g008){#F8}

###### Cross-cancer alteration summary for CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC, STAT3

  ---------------------------------------------------------------------------------------------------------------------------------------
  Cancer               Data source                 *N*    Frequency\   Multiple alterations\   Amplification\   Mutation\     Deletion\
                                                          (%)          (%, *N*)                (%, *N*)         (%, *N*)      (%, *N*)
  -------------------- --------------------------- ------ ------------ ----------------------- ---------------- ------------- -----------
  Esophagus            TCGA                        184    67.9%        7.6% (14)               56.5% (104)      2.7% (5)      1.1% (2)

  Ovarian              TCGA                        311    60.5%        2.6% (8)                53.1% (165)      2.3% (7)      2.6% (8)

  CCLE                 Novartis/Broad 2012         881    59.3%        7.8% (69)               37.1% (327)      11.9% (105)   2.4% (21)

  GBM                  TCGA                        273    59%          22.7% (62)              28.9% (79)       7% (19)       0.4% (1)

  NEPC                 Trento/Cornell/Broad 2016   107    58.9%        0.9% (1)                53.3% (57)       3.7% (4)      0.9% (1)

  Glioblastoma         TCGA 2013                   281    57.3%        117.1% (48)             33.5% (94)       6.4% (18)     0.4% (1)

  MBL                  Sickkids 2016               213    53.3%        3.3% (7)                46.5% (99)       1.9% (4)      1.9% (4)

  Head & neck          TCGA pub                    279    50.9%        4.3% (12)               39.8% (111)      4.3% (12)     0.4% (1)

  Head & neck          TCGA                        504    50.2%        4% (20)                 37.3% (188)      8.3% (42)     0.6% (3)

  Prostate             FHCRC, 2016                 136    50%          2.9% (4)                39.7% (54)       3.7% (5)      3.7% (5)

  Stomach/Esophageal   TCGA                        265    47.9%        5.3% (14)               39.2% (104)      1.9% (5)      1.5% (4)

  Pancreas             USTW                        109    47.7%        0% (0)                  37.6% (41)       4.6% (5)      5.5% (6)

  Breast               METABRIC                    2051   46.5%        0.9% (19)               43.5% (892)      2% (41)       0.1% (2)

  Ovarian              TCGA pub                    316    42.1%        1.6% (5)                37.3% (118)      1.9% (6)      1.3% (4)

  Breast               TCGA                        963    42%          1% (10)                 38l3% (369)      2% (19)       0.6% (6)

  Bladder              TCGA                        127    41.7%        7.9% (10)               28.3% (36)       4.7% (6)      0.8% (1)

  Bladder              TCGA                        127    41.7%        7.1% (9)                28.3% (36)       5.5% (7)      0.8% (1)

  Breast               TCGA 2015                   816    41.5%        1.5% (12)               37.7% (308)      2.1% (17)     0.2% (2)

  Stomach              TCGA                        393    40.5%        3.3% (13)               24.7% (97)       11.2% (44)    1.3% (5)

  Lung squ             TCGA                        177    40.1%        5.6% (10)               27.7% (49)       5.6% (10)     1.1% (2)
  ---------------------------------------------------------------------------------------------------------------------------------------

Furthermore, we applied the OncoPrint from a query for alterations in CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC, and STAT3 genes. The percentages of alterations in these genes among NEPC varied from 10--53% for individual genes (CCND1, 27%; EGFR, 21%; IL6, 25%; JAK1, 18%; JAK3, 23%; MAPK1, 10%; MYC, 53%; SOCS3, 27%; SRC, 22%; and STAT3, 21%), the MYC gene was amplified predominantly in the NEPC type (Figure [9](#F9){ref-type="fig"}, Table [4](#T4){ref-type="table"}).

![Neuroendocrine prostate cancer types frequently amplify STAT3\
We used the Oncoprint feature of the cBioPortal (<http://www.cbioportal.org>) to determine the copy number alteration frequency of each individual gene (CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC, and STAT3) in STAT3 within selected cancer subtypes.](oncotarget-09-3198-g009){#F9}

###### The percentages of alterations in CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC, STAT3

  Cancer               CCND1   EGFR   IL6    JAK1   JAK3   MAPK1   MYC    SOCS3   SRC    STAT3
  -------------------- ------- ------ ------ ------ ------ ------- ------ ------- ------ -------
  Esophagus            36%     16%    9%     3%     5%     1.6%    27%    3%      3%     4%
  Ovarian              8%      3%     4%     4%     11%    5%      41%    6%      4%     1.9%
  CCLE                 12%     15%    7%     8%     5%     7%      24%    8%      5%     6%
  GBM                  0.4%    55%    0.7%   1.1%   1.5%   1.8%    1.8%   0.4%    0.7%   1.1%
  NEPC                 27%     21%    25%    18%    23%    10%     53%    27%     22%    21%
  Glioblastoma         0.4%    53%    0.7%   1.1%   1.1%   1.4%    1.8%   0.7%    0.7%   0.7%
  MBL                  25%     8%     2.8%   4%     2.8%   1.9%    19%    6%      5%     2.3%
  Head & neck          28%     14%    1.4%   1.8%   1.8%   4%      13%    0.4%    1.8%   1.4%
  Head & neck          25%     14%    2.2%   2.4%   2.2%   4%      13%    0.2     1.8%   1.6%
  Prostate             13%     4%     6%     6%     6%     1.9%    41%    1.9%    7%     7%
  Stomach/Esophageal   12%     10%    6%     2.3%   5%     1.9%    23%    4%      5%     5%
  Pancreas             9%      1.8%   0.9%   6%     8%     7%      13%    10%     6%     6%
  Breast               17%     4%     2.8%   3%     1.9%   1.1%    27%    6%      2.7%   1.4%
  Ovarian              4%      2.2%   1.9%   1.6%   6%     2.2%    31%    2.8%    1.6%   0.6%
  Breast               16%     2.7%   1.9%   2.6%   2.4%   1%      22%    6%      2.5%   2.6
  Bladder              13%     11%    6%     5%     2.4%   4%      12%    4%      3%     1.6%
  Bladder              13%     9%     6%     5%     3%     4%      12%    4%      3%     1.6%
  Breast               16%     2.6%   1.5%   2.7%   2.6%   1.3%    21%    6%      2.8%   3%
  Stomach              8%      10%    3%     6%     3%     2.3%    15%    2%      4%     2.8
  Lung squ             12%     10%    5%     3%     4%     5%      10%    4%      2.3%   2.8%

In order to discover whether each gene pair has a significant correlation, the portal performs a Fisher's exact test. The mutual exclusivity panel analysis revealed that the co-occurrent alternations of STAT3 and CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC has statistically significant. Functional plotting of the corresponding mRNA level associated with the genetic status of STAT3 revealed that deletion of STAT3 was associated with increased mRNA expression (Figure [10](#F10){ref-type="fig"}).

![The mutual exclusivity panel analysis revealed that the co-occurrent alternations of STAT3 and CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, SRC has statistically significant\
The *P* values are determined by a Fisher's exact test, *P* \< 0.05 (<http://www.cbioportal.org/index.do?session_id=59847ef8498e5df2e2937e6b&show_samples=false&>).](oncotarget-09-3198-g010){#F10}

The cBioPortal analysis program identified 12 types of human cancer with significant CNAs in the chosen genes' signature (STAT3, CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, and SRC). The STAT3 signature was created such as to represent the structures and functions of STAT3. The CNAs of specific structural components of the STAT3 in tumors may be potential targets to prevent metastatic spread. Network view of STAT3 and other chosen genes in neuroendocrine prostate cancer was presented in Figure [11](#F11){ref-type="fig"}. The query genes, STAT3, CCND1, EGFR, IL6, JAK1, JAK3, MAPK1, MYC, SOCS3, and SRC were depicted with a thick border and neighbor genes were distributing around them.

![Interactive analysis and visualize the altered networks of STAT3 (cBio Cancer Genomics Portal)\
Darker red indicates increased frequency of alteration (defned by mutation, copy number amplifcation, or homozygous deletion) in Neuroendocrine Prostate Cancer.](oncotarget-09-3198-g011){#F11}

DISCUSSION {#s3}
==========

STAT3 has been proved to participate in the generation and development of various cancers \[[@R38]\]. Moreover, numbers of researches have shown that STAT3-targetd therapy can effectively inhibit tumor development \[[@R12]\]. However, the exact role of STAT3 overexpression in human tumors is till controversial. In order to have the compelling analysis, in the current research, we performed the analyses depend on numerous genes expression with clearly defined parameters between cancer and normal tissues. In Oncomine analysis, STAT3 was found to be unregulated in brain and CNS, gastric, head and neck, melanoma, myeloma cancer, but deregulated in breast, leukemia, liver, lymphoma, and sarcoma cancer.

To gain further insights into the role of a prognostic marker, we next investigated the association of STAT3 expression and OS in various cancers, the prognostic value of STAT3 mRNA expression was assessed using the Kaplan-Meier Plotter and PrognoScan. Overall, high levels of STAT3 gene expression result in low survival in ovarian, lung, blood, and brain cancer, however, which is not clear in breast cancer. Therefore, to assess the tumorigenic or tumor suppressor role of STAT3 in breast cancer, many previous studies have demonstrated that the protein expression was significantly up-regulated in breast cancer tissues compared with their matched normal breast tissues \[[@R39]--[@R41]\]. Furthermore, the expression of STAT3 in tumor tissues was significantly associated with a tumor, lymph node metastasis, and TNM stage in breast patients \[[@R42]\]. In addition, Kaplan-Meier analysis demonstrated that the overall survial rate in breast cancer patients with high STAT3 levels was significantly lower than that in those with low STAT3 levels \[[@R41]\].

Somatically acquired genetic, epigenetic, transcriptomic, and proteomic alternations are the major four factors in tumorigenesis \[[@R4]\]. The somatic loss-of-function or gain-of-function alterations are happened in specific genomic regions, which could indicate their potential inhibitory or carcinogenic roles, respectively \[[@R43]\]. Therefore, we used cBioPortal to identify human cancers discovered significant CAN in the STAT3-gene signature. STAT3 mutation mainly occurred in uterine cancer and existed in a hotspot in SH2 domain. From the lowest to highest dominance hierarchy, the ratio of alteration ranged over 40.1--67.9%. The particularly interest constituted the predominant pattern of amplification occurring in neuroendocrine prostate cancer (NEPC).

Subsequently, we performed cBioPortal to interactive analysis and visualize the altered networks of STAT3. From the network analysis, we can discover more information about the mechanisms of interaction among the different genes \[[@R5]\]. Figure [11](#F11){ref-type="fig"} displayed that the Network view of the STAT3 neighborhood in neuroendocrine prostate cancer, those results were better to comprehend the molecular mechanisms of STAT3 underlying cancer. After an extensive literature review on previous related studies, STAT3 is proven to involve in various tumors by impacting target genes or signal pathway, which is consistent with our bioinformatics analyses \[[@R6], [@R44]--[@R49]\]. As the previous studies revealed that STAT3 transactivates proliferative genes (*cMyc* and *CyclinD1*), prosurvival genes (*Bcl-xl* and *Survivin*) and invasive genes (*VEG-f* and *Klf-8*), leading to fast-growing tumors with highly metastatic capability \[[@R50]\]. Yuanyan Li *et al.* recently demonstrated that BMX can promote cell proliferation through STAT3 signaling pathways in cervical cancer cells \[[@R51]\], meanwhile Zhongde Zhang *et al.* revealed that STAT3 could bind promoter region of TXNDC17 for regulating its expression and mediating Taxol resistance via enhancing autophagy in human colorectal cancer cells \[[@R52]\]. Along with the mechanistic insights, identification of the cell context-dependent functions for STAT3 may help ultimately develop therapeutic strategies targeting STAT3.

In the present study, we used portals to systemically analyze the expression and prognostic value of STAT3 in cancer development, which contributes to a better understanding of molecular etiology and epidemiology of cancer, and ultimately accelerates the transformation of genomic knowledge into clinical practice. Our finding demonstrates that STAT3 might serve as a diagnostic and therapeutic target for certain types of cancer, including lung, ovarian, gastric, blood and brain cancers. However, the deep mechanism of these results remains unclear, further researches need to be performed in the future.

MATERIALS AND METHODS {#s4}
=====================

Oncomine database analysis {#s4_1}
--------------------------

Oncomine database (<https://www.oncomine.org/resource/login.html>), an online database consisting of previously published and open-access microarray data, was performed to identify the transcription level of STAT3 gene in various types of cancers \[[@R53], [@R54]\]. The mRNA expression of STAT3 in clinical cancer tissue was compared with that in normal control, using a Students' *t*-test to generate a *p* value. The parameters *p*-value \< IE-4, fold change \>2, and gene ranking in the top 10% were used to obtain the most significant STAT3 probes. Heat map was used to define the co-expression profiles of STAT3 gene in different types of cancers.

cBioPortal database analysis {#s4_2}
----------------------------

The cBioPortal for Cancer genomics is an open-access resource (<http://www.cbioportal.org/>) \[[@R55], [@R56]\], providing visualization and analyzing tool for more than 5,000 tumor samples from 105 cancer studies in TCGA pipeline. The search interface combined with customized data storage enabled researchers to interactively explore genetic alterations across samples from other cancer studies and specific genes. The term "STAT3" was searched in cBioPortal database and a cross-cancer summary was obtained for it. The search parameters included alterations (amplification, deep deletion, missense mutations), copy-number variance (CNV) from GISTIC and RNA seq data with the default setting. OS and DFS were calculated on the basis of cBioPortal's online instruction.

Kaplan--Meier plotter database analysis {#s4_3}
---------------------------------------

Kaplan-Meier Plotter (<http://kmplot.com/analysis/>) is an online database of published microarray datasets that assess the effect of 54,675 genes on survival using 10,461 cancer samples (5,143breast, 1,816 ovarian, 2,437 lungs and 1,065 gastric cancer) \[[@R57]\]. We performed the Kaplan-Meier plotter to assess the prognostic value of STAT3 expression in patients with breast, gastric, ovarian and lung cancer. The hazard ratio (HR) with 95% confidence intervals (CI) and log rank *p*-value was also computed.

Prognoscan database analysis {#s4_4}
----------------------------

PrognoScan (<http://www.prognoscan.org/>) is a comprehensive online platform for assessing potential tumor biomarkers and therapeutic targets. We used the PrognoScan platform to validate the prognostic value of STAT3 expression in patients with various types of cancers. The threshold was adjusted to cox *p*-value \< 0.05.

Identifying the protein components of STAT3 axis {#s4_5}
------------------------------------------------

We utilized the STRING analysis tool (<http://www.string-db.org/>), a database of known and predicted protein interacting, to determine interacting proteins using STAT3 as the query \[[@R58]\].

Statistical analysis {#s4_6}
--------------------

All statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software, La Jolla, CA, USA). Survival curves were plotted using the cBioPortal and Kaplan--Meier plots. All results are displayed with *P* values from a long-rank test. Similarly, with Oncomine, heatmaps. A *P* values of \< 0.05 were considered to be statistically significant.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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